Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancer
JTCVS Open · 2024-08 · 20 · 167-173
DOI: 10.1016/j.xjon.2024.05.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift JTCVS Open, 2024-08. Verfasst von Alessandro Brunelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, University of Leeds, Leeds, United Kingdom. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate the oncologic outcome of patients with hypermetabolic tumors resected by segmentectomy or lobectomy.
Methods
This was a retrospective analysis of all consecutive patients with peripheral clinical stage IA1-2 non-small cell lung cancer (January 2017-June 2023) who underwent resection by segmentectomy or lobectomy in a single center. A hypermetabolic tumor was defined as a tumor with a positron emission tomography (PET) maximum standardized uptake value >2.5. Propensity score case-matching analysis was used to generate 2 balanced groups of patients with hypermetabolic tumors operated by segmentectomy or lobectomy. Four-year overall survival (OS), event-free survival (EFS), and cancer-specific survival were compared between the matched groups.
Results
A total of 164 segmentectomies and 234 lobectomies were analyzed. There were 91 (55%) hypermetabolic tumors in the segmentectomy group versus 178 in the lobectomy group (76%), P < .001. The comparison of the matched groups with hypermetabolic tumors showed a better 4-year OS after lobectomy compared with segmentectomy (lobectomy 87%; 95% confidence interval [CI], 76-93; segmentectomy, 67%; 95% CI, 49-80; P = .029). The 4-year EFS appeared to have a better trend after lobectomy (77%; 95% CI, 65-85) compared with segmentectomy (58%; 95% CI, 39-72), P = .088. The 4-year cancer-specific survival, however, was similar between the matched groups (lobectomy, 95%; 95% CI, 86-98 vs segmentectomy, 94%; 95% CI, 78-99, P = .79).
Conclusions
Early-stage peripheral hypermetabolic tumors are associated with poorer oncologic outcomes compared with less PET-avid tumors. Despite poorer OS and EFS after segmentectomy likely caused by cancer-unrelated deaths, cancer-specific survival in this high-risk group was similar after lobectomy or segmentectomy. In well-selected patients, a high PET maximum standardized uptake value should not be considered a contraindication to segmentectomy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, University of Leeds, Leeds, United Kingdom.
- Department of Thoracic Surgery, St. James University Hospital, Leeds, United Kingdom.
Zitieren
APA
Brunelli, A., Lodhia, J., Milton, R., Nardini, M., Papagiannopoulos, K., Tcherveniakov, P., Stefanou, D., Teh, E., & Chaudhuri, N. (2024). Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancer. JTCVS Open, 20, 167-173. https://doi.org/10.1016/j.xjon.2024.05.002
Vancouver
Brunelli A, Lodhia J, Milton R, Nardini M, Papagiannopoulos K, Tcherveniakov P, et al. Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancer. JTCVS Open. 2024;20:167-173. doi:10.1016/j.xjon.2024.05.002
BibTeX
@article{Brunelli2024,
author = {Brunelli, Alessandro and Lodhia, Joshil and Milton, Richard and Nardini, Marco and Papagiannopoulos, Kostas and Tcherveniakov, Peter and Stefanou, Demetrios and Teh, Elaine and Chaudhuri, Nilanjan},
title = {Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancer},
journal = {JTCVS Open},
year = {2024},
volume = {20},
pages = {167--173},
doi = {10.1016/j.xjon.2024.05.002}
}
EUVIMED